MedPath
EMA Product

Sildenafil Actavis

Product approved by European Medicines Agency (EU)

Basic Information

Sildenafil Actavis

Regulatory Information

EMEA/H/C/001090

Authorised

December 10, 2009

September 24, 2009

17

November 13, 2023

Company Information

Iceland

Dalshraun 1 220 Hafnarfjörður

Actavis Group Ptc Ehf.

Drug Classification

Generic Medicine

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Sildenafil Actavis to be effective, sexual stimulation is required.

Overview Summary

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).

© Copyright 2025. All Rights Reserved by MedPath